Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S323000, C514S339000, C514S414000, C514S421000, C544S373000, C546S201000, C546S277700, C548S467000, C548S472000
Reexamination Certificate
active
07868008
ABSTRACT:
The present invention is directed to compounds of formula I:wherein R1, R2, R3, R4, R5, R6, R7, R8, R9and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
REFERENCES:
patent: 5175157 (1992-12-01), Psiorz et al.
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 6017919 (2000-01-01), Inaba et al.
patent: 2003/0212094 (2003-11-01), Yamabe
patent: 2005/0026976 (2005-02-01), Curtin et al.
patent: WO-99/26927 (1999-06-01), None
patent: WO-2004/031178 (2004-04-01), None
patent: WO-2005/074643 (2005-08-01), None
patent: WO-2005/085214 (2005-09-01), None
patent: WO-2005/085216 (2005-09-01), None
patent: WO-2006/020879 (2006-02-01), None
patent: WO-2006/047237 (2006-05-01), None
patent: WO-2006/091496 (2006-08-01), None
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.
Vippagunta, S.R. et. al., “Crystalline Solids”, Advanced Drug Delivery Reviews, vol. 48, pp. 3-26, 2001.
Lee et al., “The role of metabotropic glutamate receptors in Alzheimer's disease”, Acta Neurobiologiae Experimentalis, 64(1), 89-98, 2004.
Barr et al.; Journal of Organometallic Chemistry, vol. 302, No. 1, Mar. 11, 1986, pp. 117-126, XP002383544.
Hoarau C et al: Synthesis, No. 5, 2000, pp. 655-660, XP002383545.
Rys V et al: European Journal of Organic Chemistry, No. 7, Apr. 2003, pp. 1231-1237, XP002383546.
Clayden J et al: Organic Letters, vol. 2, No. 26, 2000, pp. 4229-4232 XP002345295.
Couture A et al: Tetrahedron Letters, vol. 43, No. 12, Mar. 18, 2002, pp. 2207-2210 XP004344002.
Casagrande C et al: IL Farmaco, Edizione Scientifica, vol. 27, No. 6, Jun. 1972, pp. 445-470, XP000 571647.
Bonnefous et al., Bioorganic & Medicinal Chemistry Letters, vol. 15, p. 4354-4358 (2005).
Bonnefous et al. (Merck), poster presented at the 229th National Meeting of the American Chemical Society, San Diego, CA, Mar. 2005; poster, MEDI-37.
Eric Mertz, et al, “Synthetic Receptors for CG Base Pairs”, Organic Letters, 2000, vol. 2, No. 19, pp. 2931-2934.
Sudha R. Vippagunta, et al, “Crystalline Solids”, Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
Pierre Souillac, et al., “Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery”, 1999, John Wiley & Sons, pp. 212-227.
Hyoung-Gon Lee, et al, “The Role of Metabotropic Glutamate Receptors in Alzheimer's Disease”, Acta Neurobiol Exp 2004, 64: pp. 89-98.
Clayton Joshua
Egle Ian
Empfield James
Isaac Methvin
Ma Fupeng
Astrazeneca AB
Mitchell Kenneth F.
Powers Fiona T
LandOfFree
Substituted isoindolones and their use as metabotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted isoindolones and their use as metabotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted isoindolones and their use as metabotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643095